Abstract 290 Table 1
EndpointsHTx Patients w/CDif (N=69)HTx Patients w/o CDif (N=69)P-value
Subsequent 1-year Survival 84.1% 97.1% 0.010
Subsequent 1-year Freedom from CAV 98.6% 95.7% 0.341
Subsequent 1-year Freedom from NF-MACE 84.1% 92.8% 0.078
1-year Freedom from ACR 94.2% 97.1% 0.366
1-year Freedom from AMR 92.8% 100.0% 0.021